Build a sharing economy model to assist Renyao to build a rich product line

[China Pharmaceutical network enterprise news] Furen pharmaceutical industry has always been taking the concept of "Jishi medicine as a supplement to benefit the people, and will be benevolent", taking R & D and innovation as the engine of enterprise development For a long time, the company has insisted on seeking development in innovation and taking the road of technological development In addition to innovation, Furen pharmaceutical industry is still moving steadily in the capital market, gradually leading enterprises to a multi variety and multi-scale development path Zhu Wenchen is an innovator At a meeting at the end of April this year, he suggested that if we don't innovate, we should not play in the pharmaceutical industry In Zhu Wenchen's consciousness, innovation is the original meaning of enterprise existence Zhu Wenchen, chairman of Furen Pharmaceutical Co., Ltd., with his philosophy and persistence, the R & D investment of Furen Pharmaceutical Co., Ltd accounts for nearly 6% of the total sales every year At the end of April, Furen Pharmaceutical Co., Ltd established a professional pharmaceutical company jointly with sidelung Pharmaceutical Co., a large anti-tumor and anti AIDS manufacturer in India International and domestic drug R & D laboratories, four anti-tumor drug preparation production lines (tablet, capsule, water injection, freeze-dried powder injection) and supporting equipment and facilities were completed in Guandu Industrial Park, Zhongmou, India It is estimated that by 2025, more than 50 products will be produced in Guandu Industrial Park, Zhongmou, India, which will be the research and development direction of anti-tumor drugs and anti viral drugs in China In the future, Furen pharmaceutical industry is bound to become a competitive and international pharmaceutical enterprise Of course, the success of Furen pharmaceutical industry is not only innovation In recent years, Furen pharmaceutical industry has been vigorous in the capital market Through M & A and restructuring, it has been expanding the scale of the enterprise, which makes the enterprise embark on a road of multi variety and large-scale development Meanwhile, the company has maintained a steady and rapid development through hard work, which benefits from its continuous pursuit of technological innovation and management innovation, thus laying a solid foundation for the continuous development of the enterprise Back in 1998, when Fu Ren pharmaceutical was founded, there was only one variety In order to break through the dilemma of conventional development, since 2001, the company has completed a number of mergers and acquisitions, and constantly built a huge industrial system The recent M & A case is that at the end of 2015, the company announced that the volume of M & A is much larger than that of its new drug group, in order to expand its scale in the field of Chinese patent medicine and improve its comprehensive competitiveness, industrial status and sustainable profitability In the early stage of development, the research and development strategy of "Research Institute without walls" was put forward to build the sharing economy model of Furen pharmaceutical industry Through the forms of enterprise merger and cooperation, the company has taken the route of large production capacity and multiple products, achieving today's "Furen 1000" and laying a pattern of general medicine based on the people In Zhu Wenchen's view, under the mode of sharing economy, open R & D platform and innovation management mechanism are the key to the rapid development of pharmaceutical enterprises In this process, to create a loose innovation environment and system is the key to enterprise innovation It needs the promotion of system and mechanism, the nourishment of human spirit, and also the persistence of the enterprise itself In recent years, under the leadership of Zhu Wenchen, Furen pharmaceutical industry has taken the lead in exploring a platform based economic model by using the thinking of sharing economy To sublimate the R & D strategy of "Research Institute without walls" Change the R & D thinking from vertical value chain to bilateral market thinking, and achieve the "de boundary", "de center" and "de middle" of pharmaceutical R & D institutions By building a collaborative and win-win R & D platform, it can form a siphon force, carry out the coordination of capital, products, technology, talents and other resources, realize the sharing economy mode, and explore an innovative way for the pharmaceutical industry In the past five years, the number of innovative drug R & D and application of domestic manufacturers has increased sharply However, few of these drugs are approved every year In addition, as for the research and development of generic drugs, after a new drug is approved, there will soon be many imitations and applications from many manufacturers in China It is normal that 20-30 enterprises apply at the same time, or even more than 100 enterprises may apply, which leads to a serious waste of drug research and development resources The main reasons for these results are the lack of historical accumulation of innovative drug research and development, the lack of human resources, the lack of innovative drug screening and discovery platform The infrastructure of "cloud, network and end", the production factors of big data and the economic model of sharing and cooperation are the changes of the new economy compared with the traditional economy, and also the mainstream and future development direction of the current economic development Under the background of the vigorous development of big data, an effective, convenient and high resource utilization sharing economy will emerge With unlimited demand and supply, there will be an infinite possibility for the market Zhu Wenchen believes that to solve the above problems, pharmaceutical enterprises can gather all the resource parties in the R & D industry chain on one platform through the thinking of sharing economy, similar to Alibaba's Internet model, and establish the entire drug R & D industry chain, forming a drug R & D ecosystem with shared value, coordinated development, win-win and mutual benefit, so as to promote drug R & D The rapid development of It can make funds, demands, technologies, products, talents, etc to achieve better allocation and sharing, so that the utilization rate of R & D resources and the efficiency of R & D behavior will be greatly improved, and the research topics of R & D institutions will have more extensive screening sources, more selective, targeted and directional, and can meet the personalized needs of the demander Furen pharmaceutical is building a new drug innovation science park in Shanghai, which is a R & D platform based on China and looking to the world In the future, it will form an incubation base for new drug R & D innovation and entrepreneurship, provide project R & D incubation services for new drug R & D teams around the world, and plan to attract 100 overseas returned doctors or institutions in the field of pharmaceutical R & D to enter the platform At the same time, 2000 R & D personnel will be allocated to this R & D base to solve the talent problems needed for drug R & D innovation and carry out follow-up procedural work, such as drug discovery, drug design, pre clinical research, clinical research and international registration of final drugs On this platform, only project leaders need to discover, establish new projects, and make breakthroughs The pharmaceutical industry can directly open up all links for their new drug research results, realize the industrialization and commercialization of products, establish an industrial value chain with siphon force, and promote the coordinated innovation of R & D platform through the mode of shared economic thinking To create a rich product line, we have always taken the concept of "benefiting the people with the help of world medicine" and R & D innovation as the engine of enterprise development For a long time, the company insists on seeking development in innovation and taking the road of technological development The annual investment in R & D accounts for nearly 6% of the total sales, which is far greater than the investment of less than 2% in some domestic peers As early as 2003, Furen pharmaceutical established Furen Pharmaceutical Technology Development Co., Ltd with R & D innovation as its main business In the past ten years, the company has continued to make efforts in R & D and innovation For example, in 2006, Furen Pharmaceutical Technology Center was jointly approved as "national recognized enterprise technology center" by five ministries and commissions including the national development and Reform Commission, and at the same time, it was approved by the Ministry of human resources and social security to set up "postdoctoral research workstation"; in 2007, it was approved by the science and Technology Department of Henan Province to set up "Henan traditional Chinese medicine preparation engineering technology research center"; In 2011, the company and Zhengzhou University jointly established the key laboratory; in 2012, the company was awarded the title of "top ten leading enterprises of scientific and technological innovation in Henan Province" by Henan Provincial Development and Reform Commission, science and technology department and other departments; in 2014, the Furen innovation science and Technology Park was established in the Eastern District of Zhengzhou At present, the company has been rated as one of the top ten industrial enterprises of product R & D line by China Pharmaceutical (600056, Guba) industrial information center of the Ministry of industry and information technology The company has set up professional R & D personnel and teams, with more than 300 R & D personnel and more than 30 international marketing and registration personnel Pay attention to the combination of production, learning and research Zhengzhou chemical medicine innovation platform and Beijing biological medicine innovation platform have been built Zhengdong New Area new drug innovation science park is being prepared The lab has been jointly built with China Academy of preventive medicine, Tianjin Pharmaceutical Research Institute, School of pharmacy of Zhengzhou University and other scientific research institutes to carry out long-term production university research cooperation In the research of more than 70 new drugs of three categories, the company has the ability of rapid imitation innovation The company is committed to realizing the leap from imitation innovation to original innovation, and has a strong ability of international market development For a long time, the company has made full use of various resources and technical advantages to improve its R & D and innovation capabilities Due to the emphasis on innovation and development, through the introduction of foreign advanced preparations and testing equipment, the company's production process and testing methods have reached the domestic level Since 2010, in the evaluation of R & D strength of domestic pharmaceutical enterprises by China Pharmaceutical Industry Information Center, Fu Ren has been ranked in the top three Since then, it has been ranked in the top every year For example, its subsidiary Henan furrentang Pharmaceutical Co., Ltd is a key high-tech enterprise recognized by the Ministry of science and technology of the people's Republic of China for the national torch plan, a modern science and technology demonstration enterprise of traditional Chinese medicine in Henan Province, and a technological innovation demonstration enterprise in Henan Province The company's main products are mostly traditional Chinese medicine protection varieties or national production varieties, which have a strong competitive advantage in the market In 2017, Fu Ren Pharmaceutical Co., Ltd was selected into 578 varieties in the new version of the medical insurance catalogue, with an increase of 165 varieties compared with that in 2009, with an increase of 39.95% Among them, 364 were selected into category A, with an increase of 42.754%, and 214 were selected into category B, with an increase of 35.44% It has become one of the pharmaceutical enterprises with a large number of selected varieties "Furen" trademark is recognized as Brand value is constantly improving Innovation is the essence of enterprise existence Zhu Wenchen, chairman of Furen pharmaceutical, said innovation is the essence of enterprise existence The implementation of innovation driven strategy is not only a national strategy, but also the only way for enterprises to adapt to the global competition in the future Furen pharmaceutical industry has been insisting on making common people (603883, stock bar) affordable, willing to buy, buy and have good curative effect At the same time, it always sticks to innovation as a belief In production, marketing, research and development and other aspects, it constantly invests human and material resources, and resolutely moves forward on the premise of keeping sober In recent years, cheap basic drugs are disappearing at the rate of dozens every year However, since its establishment, the direction of focusing on common people's drug use has not changed The company has been making products with great market demand and basic treatment needs of the people Produce products that people can afford, are willing to buy, can buy and have good curative effect "Common medicine, auxiliary Renzao" has been trusted by more customers Medicine is a special commodity, which is vital to human life The quality problem has attracted much attention As it carries the enterprise mission of "Jishi medicine as a supplement and benefiting the people is determined to be benevolent", the company always adheres to the quality in every stage of development "When there is a contradiction between production and quality, production gives way to quality; when there is a contradiction between cost and quality, cost gives way to quality." This is the product culture of Furen pharmaceutical industry, and also an important part of the soul of the enterprise This persistence not only enables Furen to create high-quality products, but also to guard the precious with its own spirit "Quality is life, not a little vague." That's what chairman Zhu Wenchen said "Cost gives way to quality, output gives way to quality", which